IMVT

39.41

0.10% 0.04

Dopo l'orario di chiusura: 39.41

Immunovant Inc (IMVT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché IMVT Giù? Forum Previsione

Precedente Chiudi:

$39.37

Aprire:

$39.8

Volume 24 ore:

727.07K

Relative Volume:

0.42

Capitalizzazione di mercato:

$8.09B

Reddito:

Utile/perdita netta:

$-505.61M

Rapporto P/E:

-14.23

EPS:

-2.7697

Flusso di cassa netto:

$-407.32M

1 W Prestazione:

-2.11%

1M Prestazione:

+3.11%

6M Prestazione:

+51.52%

1 anno Prestazione:

+115.12%

Intervallo 1D:

$38.70

$39.87

Intervallo di 1 settimana:

$38.00

$41.21

Portata 52W:

$14.32

$41.23

Immunovant Inc Stock (IMVT) Company Profile

Nome

Immunovant Inc

Settore

Healthcare (1071)

Industria

Biotechnology (598)

Telefono

917-410-3120

Indirizzo

1000 PARK FORTY PLAZA, DURHAM, NY

Dipendente

315

Cinguettio

Prossima data di guadagno

2026-08-10

Ultimi documenti SEC

IMVT's Discussions on Twitter

Compare IMVT vs VRTX, REGN, ARGX, RVMD, ALNY

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IMVT Immunovant Inc	39.41	8.09B	0	-505.61M	-407.32M	-2.7697
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-20	Iniziato	Bernstein	Mkt Perform
2026-01-06	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-10-14	Iniziato	Truist	Hold
2025-07-10	Ripresa	Goldman	Neutral
2025-03-03	Iniziato	Jefferies	Hold
2025-01-03	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-10-10	Ripresa	Raymond James	Outperform
2024-10-09	Reiterato	Oppenheimer	Outperform
2024-03-28	Iniziato	Oppenheimer	Outperform
2024-03-13	Iniziato	Goldman	Buy
2024-02-20	Iniziato	JP Morgan	Overweight
2024-02-15	Iniziato	Wolfe Research	Outperform
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-10-13	Aggiornamento	UBS	Neutral → Buy
2023-09-26	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-05-01	Iniziato	BofA Securities	Buy
2023-04-25	Iniziato	Citigroup	Buy
2023-03-31	Iniziato	Piper Sandler	Overweight
2023-03-30	Iniziato	Stifel	Buy
2023-02-15	Iniziato	Cantor Fitzgerald	Overweight
2023-02-13	Aggiornamento	Guggenheim	Neutral → Buy
2023-01-03	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-09-26	Downgrade	UBS	Buy → Neutral
2021-12-08	Iniziato	Wells Fargo	Equal Weight
2021-08-03	Downgrade	Robert W. Baird	Outperform → Neutral
2021-08-02	Downgrade	Credit Suisse	Neutral → Underperform
2021-06-01	Downgrade	Guggenheim	Buy → Neutral
2021-06-01	Downgrade	Stifel	Buy → Hold
2020-10-28	Iniziato	UBS	Buy
2020-10-12	Iniziato	Guggenheim	Buy
2020-10-08	Iniziato	Stifel	Buy
2020-10-02	Iniziato	Credit Suisse	Outperform
2020-08-26	Reiterato	H.C. Wainwright	Buy
2020-08-25	Iniziato	Raymond James	Outperform
2020-07-29	Iniziato	H.C. Wainwright	Buy
2020-02-24	Iniziato	SVB Leerink	Outperform

Mostra tutto

Immunovant Inc Borsa (IMVT) Ultime notizie

Jul 25, 2026

Immunovant CFO Tiago Girao sells $263,014 in company stock By Investing.com - Investing.com Nigeria

Jul 25, 2026

Jul 24, 2026

Immunovant director Atul Pande sells $59,699 in shares By Investing.com - Investing.com Canada

Jul 24, 2026

Immunovant CTO Jay Stout Executes Share Sale to Meet Tax Obligations Post-RSU Vesting - Kalkine Media

Jul 24, 2026

Jul 23, 2026

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - The Manila Times

Jul 23, 2026

Jul 22, 2026